Trial · NCT05103332
Outcomes45
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 45
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Indapamide: Change From Baseline at Month 3 in 24-hour Mean SBP Assessed by ABPM - Censored Data | Baseline and Month 3 | The mFAS included all randomized participants who received any amount of study drug. Analysis was grouped according to the randomized treatment arm. Overall number analyzed is the number of participants with data available for analysis at Month 3. | mmHg | LEAST_SQUARES_MEAN |
| PRIMARY | Amlodipine: Change From Baseline at Month 3 in 24-hour Mean SBP Assessed by ABPM - Censored Data | Baseline and Month 3 | The mFAS included all randomized participants who received any amount of study drug. Analysis was grouped according to the randomized treatment arm. Overall number analyzed is the number of participants with data available for analysis at Month 3. | mmHg | LEAST_SQUARES_MEAN |
| PRIMARY | Olmesartan: Change From Baseline at Month 3 in 24-hour Mean SBP Assessed by ABPM - Censored Data | Baseline and Month 3 | The mFAS included all randomized participants who received any amount of study drug. Analysis was grouped according to the randomized treatment arm.~Overall number analyzed is the number of participants with data available for analysis at Month 3. | mmHg | LEAST_SQUARES_MEAN |
| SECONDARY | Indapamide: Change From Baseline at Month 3 in Office SBP - Censored Data | Baseline and Month 3 | The mFAS included all randomized participants who received any amount of study drug. Analysis was grouped according to the randomized treatment arm. Overall number analyzed is the number of participants with data available for analysis at Month 3. | mmHg | LEAST_SQUARES_MEAN |
| SECONDARY | Indapamide: Time-adjusted Change From Baseline Through Month 6 in 24-hour Mean SBP, Assessed by ABPM - All Collected Data | Baseline through Month 6 | The mFAS included all randomized participants who received any amount of study drug. Analysis was grouped according to the randomized treatment arm. Overall number analyzed is the number of participants with data available for analysis at Month 6. | mmHg | LEAST_SQUARES_MEAN |
| SECONDARY | Indapamide: Time-adjusted Change From Baseline Through Month 6 in Office SBP - All Collected Data | Baseline through Month 6 | The mFAS included all randomized participants who received any amount of study drug. Analysis was grouped according to the randomized treatment arm. Overall number analyzed is the number of participants with data available for analysis at Month 6. | mmHg | LEAST_SQUARES_MEAN |
| SECONDARY | Indapamide: Percentage of Participants With 24-hour Mean SBP <130 mmHg and/or Reduction From Baseline ≥20 mmHg Assessed by ABPM Without Escape Antihypertensive Medications at Month 6 | Month 6 | The mFAS included all randomized participants who received any amount of study drug. Analysis was grouped according to the randomized treatment arm. Overall number analyzed is the number of participants with data available for analysis at Month 6. | percentage of participants | NUMBER |
| SECONDARY | Indapamide: Change From Baseline at Month 3 in 24-hour Mean Diastolic Blood Pressure (DBP), Assessed by ABPM - Censored Data | Baseline and Month 3 | The mFAS included all randomized participants who received any amount of study drug. Analysis was grouped according to the randomized treatment arm. Overall number analyzed is the number of participants with data available for analysis at Month 3. | mmHg | LEAST_SQUARES_MEAN |
| SECONDARY | Indapamide: Change From Baseline at Month 3 in Office DBP - Censored Data | Baseline and Month 3 | The mFAS included all randomized participants who received any amount of study drug. Analysis was grouped according to the randomized treatment arm. Overall number analyzed is the number of participants with data available for analysis at Month 3. | mmHg | LEAST_SQUARES_MEAN |
| SECONDARY | Indapamide: Time-adjusted Change From Baseline Through Month 3 in 24-hour Mean SBP and DBP, Assessed by ABPM - Censored Data | Baseline through Month 3 | The mFAS included all randomized participants who received any amount of study drug. Analysis was grouped according to the randomized treatment arm. Overall number analyzed is the number of participants with data available for analysis at Month 3. | mmHg | LEAST_SQUARES_MEAN |
| SECONDARY | Indapamide: Time-adjusted Change From Baseline in Office SBP and DBP Through Month 3 - Censored Data | Baseline through Month 3 | The mFAS included all randomized participants who received any amount of study drug. Analysis was grouped according to the randomized treatment arm. Overall number analyzed is the number of participants with data available for analysis at Month 3. | mmHg | LEAST_SQUARES_MEAN |
| SECONDARY | Indapamide: Change From Baseline at Month 6 in 24-hour Mean SBP and DBP, Assessed by ABPM - All Collected Data | Baseline and Month 6 | The mFAS included all randomized participants who received any amount of study drug. Analysis was grouped according to the randomized treatment arm. Overall number analyzed is the number of participants with data available for analysis at Month 6. | mmHg | LEAST_SQUARES_MEAN |
| SECONDARY | Indapamide: Change From Baseline at Month 6 in Office SBP and DBP - All Collected Data | Baseline and Month 6 | The mFAS included all randomized participants who received any amount of study drug. Analysis was grouped according to the randomized treatment arm. Overall number analyzed is the number of participants with data available for analysis at Month 6. | mmHg | LEAST_SQUARES_MEAN |
| SECONDARY | Indapamide: Time-adjusted Change From Baseline Through Month 6 in 24-hour Mean DBP, Assessed by ABPM - All Collected Data | Baseline through Month 6 | The mFAS included all randomized participants who received any amount of study drug. Analysis was grouped according to the randomized treatment arm. Overall number analyzed is the number of participants with data available for analysis at Month 6. | mmHg | LEAST_SQUARES_MEAN |
| SECONDARY | Indapamide: Time-adjusted Change From Baseline Through Month 6 in Office DBP - All Collected Data | Baseline through Month 6 | The mFAS included all randomized participants who received any amount of study drug. Analysis was grouped according to the randomized treatment arm. Overall number analyzed is the number of participants with data available for analysis at Month 6. | mmHg | LEAST_SQUARES_MEAN |
| SECONDARY | Indapamide: Change From Baseline in Daytime and Nighttime SBP and DBP by ABPM at Each Visit - All Collected Data | Baseline, and Month 2, 3 and 6 | The mFAS included all randomized participants who received any amount of study drug. Analysis was grouped according to the randomized treatment arm. Number analyzed are unique number of participants out of all the assessed participants who were evaluable for the specified category. Different participants may have contributed data for each category. | mmHg | LEAST_SQUARES_MEAN |
| SECONDARY | Indapamide: Percent Change From Baseline in Serum Angiotensinogen (AGT) | Baseline, Week 2 and Months 1, 2, 3, 4, 5 and 6 | Modified Pharmacodynamic (PD) Analysis Set included all participants who received at least 1 full dose of study drug. All by-treatment analyses based on the Modified PD Analysis Set were grouped according to the treatment actually received. Number analyzed are unique number of participants out of all the assessed participants who were evaluable for the specified category. Different participants may have contributed data for each category. | percent change | MEAN |
| SECONDARY | Amlodipine: Change From Baseline at Month 3 in Office SBP - Censored Data | Baseline and Month 3 | The mFAS included all randomized participants who received any amount of study drug. Analysis was grouped according to the randomized treatment arm. Overall number analyzed is the number of participants with data available for analysis at Month 3. | mmHg | LEAST_SQUARES_MEAN |
| SECONDARY | Amlodipine: Time-adjusted Change From Baseline Through Month 6 in 24-hour Mean SBP, Assessed by ABPM - All Collected Data | Baseline through Month 6 | The mFAS included all randomized participants who received any amount of study drug. Analysis was grouped according to the randomized treatment arm. Overall number analyzed is the number of participants with data available for analysis at Month 6. | mmHg | LEAST_SQUARES_MEAN |
| SECONDARY | Amlodipine: Time-adjusted Change From Baseline Through Month 6 in Office SBP - All Collected Data | Baseline through Month 6 | The mFAS included all randomized participants who received any amount of study drug. Analysis was grouped according to the randomized treatment arm. Overall number analyzed is the number of participants with data available for analysis at Month 6. | mmHg | LEAST_SQUARES_MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05103332/outcomes